Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1

Blood

Volumn 117, Issue 18, 2011, Pages 4691-4695

  Rajkumar, S Vincent ^a   Harousseau, Jean Luc ^b   Durie, Brian ^c   Anderson, Kenneth C ^d   Dimopoulos, Meletios ^e   Kyle, Robert ^a   Blade, Joan ^f   Richardson, Paul ^d   Orlowski, Robert ^g   Siegel, David ^h   Jagannath, Sundar ⁱ   Facon, Thierry ^j   Avet Loiseau, Hervé ^b   Lonial, Sagar ^k   Palumbo, Antonio ^l   Zonder, Jeffrey ^m   Ludwig, Heinz ⁿ   Vesole, David ^h   Sezer, Orhan ^o   Munshi, Nikhil C ^d,p   San Miguel, Jesus ^q,r   more..

^a MAYO CLINIC   (United States)

^b UNIVERSITÉ DE NANTES   (France)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF ATHENS   (Greece)

^f HOSPITAL CLÍNIC   (Spain)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h John Theurer Cancer Center   (United States)

ⁱ MOUNT SINAI MEDICAL CENTER   (United States)

^j UNIV LILLE   (France)

^k EMORY CLINIC   (United States)

^l UNIVERSITY OF TURIN   (Italy)

^m KARMANOS CANCER INSTITUTE   (United States)

ⁿ WILHELMINEN HOSPITAL   (Austria)

^o UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^p VA BOSTON HEALTHCARE SYSTEM   (United States)

^q HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^r UNIVERSITY OF SALAMANCA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN; M PROTEIN;

BONE LESION; BONE MARROW TRANSPLANTATION; BONE PAIN; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CELL CLONING; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CONSENSUS; CREATININE BLOOD LEVEL; DISEASE COURSE; ELECTROPHORESIS; FLOW CYTOMETRY; HUMAN; HYPERCALCEMIA; HYPERVISCOSITY SYNDROME; IMMUNOCHEMISTRY; IMMUNOPHENOTYPING; LIGHT CHAIN; MYELOMA; OVERALL SURVIVAL; PLASMA CELL; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SALVAGE THERAPY; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 79955977910     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-299487     Document Type: Conference Paper

References (15)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962-2972.
2. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [see comment]. N Engl J Med. 2005;352(24):2487-2498. (Pubitemid 41007864)
3. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
4. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609- 2617. (Pubitemid 36741588)
5. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22(2):231-239. (Pubitemid 351250526)
6. Niesvizky R, Richardson PG, Rajkumar SV, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008;143(1):46-53.
7. Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473. (Pubitemid 44264086)
8. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT, European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123. (Pubitemid 28435189)
9. Lonial S, Gertz MA. Eliminating the complete response penalty from myeloma response assessment. Blood. 2008;111(6):3297-3298.
10. Rajkumar SV, Durie BG. Eliminating the complete response penalty from myeloma response criteria [comment]. Blood. 2008;111(12):5759-5760.
11. Chee CE, Kumar S, Larson DR, et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood. 2009;114(13):2617-2618.
12. Durie BGM, Rajkumar SV. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma. Leukemia. 2007; 21(4):821.
13. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1): 3-9.
14. Mateos M-V, Hernandez J-M, Hernandez M-T, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108(7):2165-2172. (Pubitemid 44497496)
15. Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42(11): 1539-1543. (Pubitemid 44137426)